Navigation Links
Cincinnati Children's Issued Patent Covering Individualized Medication Dosing Technology
Date:12/2/2013

MASON, Ohio and CINCINNATI, Dec. 2, 2013 /PRNewswire/ -- Cincinnati Children's Hospital Medical Center (CCHMC) and Assurex Health today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,589,175 encompassing the "Optimization and Individualization of Medication Selection and Dosing" by Cincinnati Children's inventors Drs. Tracy A. Glauser, Richard J. Wenstrup*, Alexander A. Vinks, and John P. Pestian. The CCHMC patent covers methods for optimizing dosing regimens for medications utilizing population models, genotype, and clinical information to treat patients with neuropsychiatric and other disorders.  Assurex Health is the exclusive worldwide licensee of the technology covered under the CCHMC patent and has developed pharmacogenomic tests for psychiatric, ADHD, and pain medications commercialized under the GeneSight® brand.

The Cincinnati Children's invention provides a mechanism for translating "one size fits all" drug dosing into individualized dosing based on a person's genetic and non-heritable characteristics. The methods of the invention can be applied to correct for the variability seen in drug metabolism due to genetic polymorphisms combined with the variability resulting from non-genetic factors. The results provide a way to standardize the impact of various fixed factors, such as a patient's genetic variability, and dynamic factors, such as drug-drug and drug-environment interactions or patient drug-adherence. As a result, the starting and target doses for neuropsychiatric and other medications can be determined without the need for metabolic data.

GeneSight is a unique pharmacogenomic treatment decision support tool that tests for clinically important genetic variants affecting a patient's response to neuropsychiatric medications. Prescribing a medication that may be more likely to succeed because it is tailored to an individual patient's genetic profile enables clinicians to better manage their patient's condition and improve outcomes. For example, the recently published La Crosse clinical study showed a four-fold greater improvement in symptoms for patients whose medications were switched from their initial medications that were genetically discordant with their GeneSight profile. Furthermore, physicians for 94% of the GeneSight-guided patients either switched their patients to genetically appropriate medications or adjusted their medication dosages according to the GeneSight report.

"The Cincinnati Children's patent represents a significant advance in pharmacogenomic-directed prescribing. The addition of dosing information to our GeneSight products will enhance their value as the premier treatment decision support products that help clinicians individualize the selection of psychotropic and other medications for their patients," said James S. Burns, CEO of Assurex Health. "Assurex Health was founded to develop and commercialize cutting-edge pharmacogenomic research at CCHMC. The issuance of this dose selection patent represents another milestone in translating state-of-the-art pharmacogenomic products to support the treatment of patients with neuropsychiatric and other disorders."

"Individualizing both the selection and dosing of medications will improve patient outcomes by providing objective, evidence-based information to tailor treatment programs," said Tracy A. Glauser, M.D., Associate Director, Cincinnati Children's Research Foundation and lead inventor on the CCHMC patent. "The issuance of this patent points to the importance of pharmacogenomic-directed prescribing and its potential to improve patient care in routine clinical practice."  

About Assurex Health
Assurex Health is a personalized medicine company that specializes in pharmacogenomics and is dedicated to helping physicians determine the right medication for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Assurex Health has licensed technology from Mayo Clinic and Cincinnati Children's Hospital Medical Center. Cincinnati Children's has a financial interest in the technology referenced in this news release.

For more information about Assurex Health, please visit www.assurexhealth.com.

About Cincinnati Children's Hospital Medical Center
Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in the U.S. News and World Report's 2013 Best Children's Hospitals ranking. It is ranked #1 for cancer and in the top 10 for nine of 10 pediatric specialties. Cincinnati Children's, a non-profit organization, is one of the top three recipients of pediatric research grants from the National Institutes of Health, and a research and teaching affiliate of the University of Cincinnati College of Medicine. The Cincinnati Children's Research Foundation is one of the largest pediatric research centers in the nation, receiving over $150 million in grants annually and employs more than 500 faculty in over 50 academic departments. The medical center is recognized internationally for improving child health and transforming delivery of care through fully integrated, globally recognized research, education, and innovation. Additional information can be found at www.cincinnatichildrens.org.  Connect on the Cincinnati Children's blog, via Facebook and on Twitter. 

About GeneSight
GeneSight is a laboratory-developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient's unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual's response to drug treatments, manufacturers' FDA approved drug labels, peer reviewed scientific and clinical publications, and proven drug pharmacology.  Quick turnaround time, combined with a customized report of the patient's genomic makeup, clinical experience, and other factors can provide information to help a physician make personalized drug treatment choices for each patient.

* Richard J. Wenstrup currently serves as Chief Medical Officer at Myriad Genetics, Inc.


'/>"/>
SOURCE Assurex Health
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cincinnati based Radiology Group signs with Comprehensive Medical Practice Management
2. New U.S. Patent Issued To Dyadic International
3. Positive Generex Data Underscores Cancer Immunotherapy Forecast Issued by Citi
4. Patent Issued In China For EntreMeds Lead Drug Candidate ENMD-2076
5. Patent Issued In U.S. For EntreMeds 2ME2 In Rheumatoid Diseases
6. LamdaGen Corporation Issued United States Patent for Diagnostics on Plasmonic-Based Nanosensors
7. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
8. DioGenix Issued Seminal Patent for Diagnosing Early-stage Neurological Diseases
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Southern Home Medical Once Again Reduces The Companys Issued And Outstanding Preferred Shares
11. Vomaris patent estate grows to six issued U.S. patents and three granted international patents with U.S. Pat. No. 8,224,439
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... , July 26, 2017 E.I. Medical Imaging ... the Bimini SharkLab to custom design the worlds first ultrasound system ... sharks in their native habitat. In preparation for a ... Channel,s Shark Week, Dr. Guttridge approached EIMI with the ... diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 /PRNewswire/ ... drugs to treat rare nervous system diseases, has concluded a ... and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before ... promising results in a Phase 2 study conducted in ... in the United States ...
Breaking Medicine Technology:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... services business of UnitedHealth Group (NYSE: UNH), has made a multi-million dollar partnership ... affected by post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBI) over the ...
(Date:8/20/2017)... ... ... Are you an adult with gluten intolerance or Celiac disease living with ... participating in a research study that focuses on family interactions when dealing with dietary ... aspects of adults who have gluten sensitivities who cohabitate with other adults who may ...
(Date:8/19/2017)... , ... August 19, 2017 , ... ... that it is the first organization with pending recognition status from the Centers ... Program (“DPP”) via group telehealth classes and live video conferencing. , The ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... joined its Orlando location as an interventional pain management physician. He brings a ... the treatment of migraine headaches, and significant experience in spinal cord stimulation for ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... International, LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport ... a definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner ...
Breaking Medicine News(10 mins):